FDA Puts Strict Limits on Oral Ketoconazole Use

			July 26, 2013
				SILVER SPRING, Md. -- Oral ketoconazole (Nizoral) should never be used as first-line therapy for any fungal infection because of the risk of liver toxicity and interactions with other drugs, the FDA said Friday Fuente:  http://www.medpagetoday.com/InfectiousDisease/GeneralInfectiousDisease/40710?isalert=1&uun=g419731d167R5519153u&utm_source=breaking-news&utm_medium=email&utm_campaign=breaking-news&xid=NL_breakingnews_2013-07-26

AMPLIFY: Apixaban in acute VTE as effective but safer than standard anticoagulation

Amsterdam, the Netherlands - The oral factor Xa inhibitor apixaban (Eliquis, Pfizer/Bristol-Myers Squibb) was as effective as standard enoxaparin plus warfarin in treating acute venous thromboembolism (VTE) in a large randomized trial, one in which treatment with apixaban also led to a 69% drop in risk of major bleeding complications [1].

"The efficacy of apixaban in the patients with pulmonary embolism was similar to that in patients with deep vein thrombosis [DVT], and the relative effect was maintained in the approximately 40% of patients who presented with extensive disease," write Dr Giancarlo Agnelli (University of Perugia, Italy) and associates, in the New England Journal of Medicine.

Their report on the Apixaban for the Initial Management of Pulmonary Embolism and Deep-Vein Thrombosis as First-Line Therapy (AMPLIFY) trial, conducted at 358 centers in 28 countries, was slated for publication July 1, 2013 in conjunction with the study's scheduled presentation here at the 2013 Congress of the International Society on Thrombosis and Haemostasis. The New England Journal of Medicine lifted its embargo on AMPLIFY coverage on June 30, following, it said, an embargo break by Reuters

 

Artículo completo: http://www.theheart.org/article/1557507.do?utm_medium=email&utm_source=20130705_topStories&utm_campaign=newsletter